(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 30 January 2003 (30.01.2003)

PCT

(10) International Publication Number WO 03/008610 A2

(51) International Patent Classification7:

C12P 13/00

(21) International Application Number: PCT/EP02/07368

(22) International Filing Date:

3 July 2002 (03.07.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

101 35 053.8 60/306,869 18 July 2001 (18.07.2001) DE 23 July 2001 (23.07.2001) US

(71) Applicant (for all designated States except US): DE-GUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düsseldorf (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): RIEPING, Mechthild [DE/DE]; Mönkebergstrasse 1, 33619 Bielefeld (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— of inventorship (Rule 4.17(iv)) for US only

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE ENTEROBACTERIACEAE FAMILY WHICH CONTAIN AN ENHANCED PFKB GENE



(57) Abstract: The invention relates to a process for the preparation of L-amino acids, in particular L-threonine, in which the following steps are carried out: a) fermentation of microorganisms of the Enterobacteriaceae family which produce the desired L-amino acid and in which at least the pfkB gene, or the nucleotide sequence which codes for this, is enhanced, in particular over-expressed, b) concentration of the desired L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the desired L-amino acid.

3/008610 A2

Process for the Preparation of L-Amino Acids using Strains of the Enterobacteriaceae Family which Contain an Enhanced pfkB Gene

Field of the Invention

5 This invention relates to a process for the preparation of L-amino acids, in particular L-threonine, using strains of the Enterobacteriaceae family in which at least the pfkB gene is enhanced.

Prior Art

- 10 L-Amino acids, in particular L-threonine, are used in human medicine and in the pharmaceuticals industry, in the foodstuffs industry and very particularly in animal nutrition.
- It is known to prepare L-amino acids by fermentation of strains of Enterobacteriaceae, in particular Escherichia coli (E. coli) and Serratia marcescens. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as e.g.
- 20 stirring and supply of oxygen, or the composition of the nutrient media, such as e.g. the sugar concentration during the fermentation, or the working up to the product form, by e.g. ion exchange chromatography, or the intrinsic output properties of the microorganism itself.
- Methods of mutagenesis, selection and mutant selection are used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites, such as e.g. the threonine analogue α -amino- β -hydroxyvaleric acid (AHV), or are auxotrophic for
- 30 metabolites of regulatory importance and produce L-amino acid, such as e.g. L-threonine, are obtained in this manner.

Methods of the recombinant DNA technique have also been employed for some years for improving the strain of strains of the Enterobacteriaceae family which produce Lamino acids, by amplifying individual amino acid biosynthesis genes and investigating the effect on the production.

Object of the Invention

The object of the invention is to provide new measures for improved fermentative preparation of L-amino acids, in particular L-threonine.

Summary of the Invention

The invention provides a process for the fermentative preparation of L-amino acids, in particular L-threonine, using microorganisms of the Enterobacteriaceae family which in particular already produce L-amino acids and in which at least the nucleotide sequence which codes for the pfkB gene is enhanced.

Detailed Description of the Invention

Where L-amino acids or amino acids are mentioned in the

20 following, this means one or more amino acids, including
their salts, chosen from the group consisting of Lasparagine, L-threonine, L-serine, L-glutamate, L-glycine,
L-alanine, L-cysteine, L-valine, L-methionine, Lisoleucine, L-leucine, L-tyrosine, L-phenylalanine, L
25 histidine, L-lysine, L-tryptophan and L-arginine. LThreonine is particularly preferred.

The term "enhancement" in this connection describes the increase in the intracellular activity of one or more enzymes or proteins in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or a gene or allele which codes for a corresponding enzyme or

20

protein with a high activity, and optionally combining these measures.

By enhancement measures, in particular over-expression, the activity or concentration of the corresponding protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 2000%, based on that of the wild-type protein or the activity or concentration of the protein in the starting microorganism.

- 10 The process comprises carrying out the following steps:
 - a) fermentation of microorganisms of the Enterobacteriaceae family in which at least the pfkB gene is enhanced,
- b) concentration of the corresponding L-amino acid in the medium or in the cells of the microorganisms of the Enterobacteriaceae family, and
 - c) isolation of the desired L-amino acid, constituents of the fermentation broth and/or the biomass in its entirety or portions (> 0 to 100 %) thereof optionally remaining in the product.

The microorganisms which the present invention provides can produce L-amino acids from glucose, sucrose, lactose, fructose, maltose, molasses, optionally starch, optionally cellulose or from glycerol and ethanol. They are

- 25 representatives of the Enterobacteriaceae family chosen from the genera Escherichia, Erwinia, Providencia and Serratia. The genera Escherichia and Serratia are preferred. Of the genus Escherichia the species Escherichia coli and of the genus Serratia the species Serratia
- 30 marcescens are to be mentioned in particular.

Suitable strains, which produce L-threonine in particular, of the genus Escherichia, in particular of the species Escherichia coli, are, for example

Escherichia coli TF427

5 Escherichia coli H4578
Escherichia coli KY10935
Escherichia coli VNIIgenetika MG442
Escherichia coli VNIIgenetika M1
Escherichia coli VNIIgenetika 472T23

10 Escherichia coli BKIIM B-3996
Escherichia coli kat 13
Escherichia coli KCCM-10132.

Suitable L-threonine-producing strains of the genus Serratia, in particular of the species Serratia marcescens, 15 are, for example

> Serratia marcescens HNr21 Serratia marcescens TLr156 Serratia marcescens T2000.

Strains from the Enterobacteriaceae family which produce L-20 threonine preferably have, inter alia, one or more genetic or phenotypic features chosen from the group consisting of: resistance to α -amino- β -hydroxyvaleric acid, resistance to thialysine, resistance to ethionine, resistance to α methylserine, resistance to diaminosuccinic acid, 25 resistance to α -aminobutyric acid, resistance to borrelidin, resistance to rifampicin, resistance to valine analogues, such as, for example, valine hydroxamate, resistance to purine analogues, such as, for example, 6dimethylaminopurine, a need for L-methionine, optionally a 30 partial and compensable need for L-isoleucine, a need for meso-diaminopimelic acid, auxotrophy in respect of threonine-containing dipeptides, resistance to L-threonine, resistance to L-homoserine, resistance to L-lysine, resistance to L-methionine, resistance to L-glutamic acid,

resistance to L-aspartate, resistance to L-leucine, resistance to L-phenylalanine, resistance to L-serine, resistance to L-cysteine, resistance to L-valine, sensitivity to fluoropyruvate, defective threonine 5 dehydrogenase, optionally an ability for sucrose utilization, enhancement of the threonine operon, enhancement of homoserine dehydrogenase I-aspartate kinase I, preferably of the feed back resistant form, enhancement of homoserine kinase, enhancement of threonine synthase, 10 enhancement of aspartate kinase, optionally of the feed back resistant form, enhancement of aspartate semialdehyde dehydrogenase, enhancement of phosphoenol pyruvate carboxylase, optionally of the feed back resistant form, enhancement of phosphoenol pyruvate synthase, enhancement 15 of transhydrogenase, enhancement of the RhtB gene product, enhancement of the RhtC gene product, enhancement of the Yfik gene product, enhancement of a pyruvate carboxylase, and attenuation of acetic acid formation.

It has been found that microorganisms of the
20 Enterobacteriaceae family produce L-amino acids, in
particular L-threonine, in an improved manner after
enhancement, in particular over-expression, of the pfkB
gene.

The nucleotide sequences of the genes of Escherichia coli
25 belong to the prior art and can also be found in the genome
sequence of Escherichia coli published by Blattner et al.
(Science 277: 1453-1462 (1997)).

The following information, inter alia, on the pfkB gene is known from the prior art:

30 Description: 6-Phosphofructokinase isoenzyme 2

EC No.: 2.7.1.11

Reference: Daldal; Gene 28(3): 337-342 (1984); Guixe;

Archieves of Biochemistry and Biophysics 376(2): 313-319 (2000); Torres et al.;

Biochemical Journal 327(3): 675-684 (1997)

5 Accession No.: AE000267

The nucleic acid sequences can be found in the databanks of the National Center for Biotechnology Information (NCBI) of the National Library of Medicine (Bethesda, MD, USA), the nucleotide sequence databank of the European Molecular

10 Biologies Laboratories (EMBL, Heidelberg, Germany or Cambridge, UK) or the DNA databank of Japan (DDBJ, Mishima, Japan).

The genes described in the text references mentioned can be used according to the invention. Alleles of the genes which result from the degeneracy of the genetic code or due to "sense mutations" of neutral function can furthermore be used.

To achieve an enhancement, for example, expression of the genes or the catalytic properties of the proteins can be 20 increased. The two measures can optionally be combined.

To achieve an over-expression, the number of copies of the corresponding genes can be increased, or the promoter and regulation region or the ribosome binding site upstream of the structural gene can be mutated. Expression cassettes

25 which are incorporated upstream of the structural gene act in the same way. By inducible promoters, it is additionally possible to increase the expression in the course of fermentative L-threonine production. The expression is likewise improved by measures to prolong the life of the m-RNA. Furthermore, the enzyme activity is also increased by preventing the degradation of the enzyme protein. The genes or gene constructs can either be present in plasmids with a varying number of copies, or can be integrated and amplified in the chromosome.

Alternatively, an over-expression of the genes in question can furthermore be achieved by changing the composition of the media and the culture procedure.

Instructions in this context can be found by the expert,

inter alia, in Chang and Cohen (Journal of Bacteriology
134: 1141-1156 (1978)), in Hartley and Gregori (Gene 13:
347-353 (1981)), in Amann and Brosius (Gene 40: 183-190
(1985)), in de Broer et al. (Proceedings of the National
Academy of Sciences of the United States of America 80: 21
10 25 (1983)), in LaVallie et al. (BIO/TECHNOLOGY 11: 187-193
(1993)), in PCT/US97/13359, in Llosa et al. (Plasmid 26:
222-224 (1991)), in Quandt and Klipp (Gene 80: 161-169
(1989)), in Hamilton et al. (Journal of Bacteriology 171:
4617-4622 (1989)), in Jensen and Hammer (Biotechnology and

Bioengineering 58: 191-195 (1998)) and in known textbooks
of genetics and molecular biology.

Plasmid vectors which are capable of replication in Enterobacteriaceae, such as e.g. cloning vectors derived from pACYC184 (Bartolomé et al.; Gene 102: 75-78 (1991)), pTrc99A (Amann et al.; (Gene 69: 301-315 (1988)) or pSC101 derivatives (Vocke and Bastia; Proceedings of the National Academy of Sciences of the United States of America 80 (21): 6557-6561 (1983)) can be used. A strain transformed with a plasmid vector, where the plasmid vector carries at least the pfkB gene, or the nucleotide sequence which codes for this, can be employed in a process according to the invention.

It is also possible to transfer mutations which affect the expression of the particular gene into various strains by sequence exchange (Hamilton et al.; (Journal of Bacteriology 171: 4617-4622 (1989)), conjugation or transduction.

It may furthermore be advantageous for the production of L-amino acids, in particular L-threonine, with strains of the

Enterobacteriaceae family, in addition to enhancement of the pkfB gene, for one or more enzymes of the known threonine biosynthesis pathway or enzymes of anaplerotic metabolism or enzymes for the production of reduced 5 nicotinamide adenine dinucleotide phosphate or enzymes of glycolysis or PTS enzymes or enzymes of sulfur metabolism to be enhanced.

Thus, for example, at the same time one or more of the genes chosen from the group consisting of

- the thrABC operon which codes for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase (US-A-4,278,765),
 - the pyc gene of Corynebacterium glutamicum which codes for pyruvate carboxylase (WO 99/18228),
- the pps gene which codes for phosphoenol pyruvate synthase (Molecular and General Genetics 231(2): 332-336 (1992)),
 - the ppc gene which codes for phosphoenol pyruvate carboxylase (Gene 31: 279-283 (1984)),
- the pntA and pntB genes which code for transhydrogenase
 (European Journal of Biochemistry 158: 647-653 (1986)),
 - the rhtB gene which imparts homoserine resistance (EP-A-0 994 190),
- the mgo gene which codes for malate:quinone
 oxidoreductase (WO 02/06459),
 - the rhtC gene which imparts threonine resistance (EP-A-1 013 765),
 - the thrE gene of Corynebacterium glutamicum which codes for the threonine export protein (WO 01/92545),

WO 03/008610

• the gdhA gene which codes for glutamate dehydrogenase (Nucleic Acids Research 11: 5257-5266 (1983); Gene 23: 199-209 (1983)),

9

- the hns gene which codes for the DNA-binding protein
 5 HLP-II (Molecular and General Genetics 212: 199-202
 (1988)),
 - the pgm gene which codes for phosphoglucomutase (Journal of Bacteriology 176: 5847-5851 (1994)),
- the fba gene which codes for fructose biphosphate 10 aldolase (Biochemical Journal 257: 529-534 (1989)),
 - the ptsH gene of the ptsHIcrr operon which codes for the phosphohistidine protein hexose phosphotransferase of the phosphotransferase system PTS (Journal of Biological Chemistry 262: 16241-16253 (1987)),
- the ptsI gene of the ptsHIcrr operon which codes for enzyme I of the phosphotransferase system PTS (Journal of Biological Chemistry 262: 16241-16253 (1987)),
- the crr gene of the ptsHIcrr operon which codes for the glucose-specific IIA component of the phosphotransferase system PTS (Journal of Biological Chemistry 262: 16241-16253 (1987)),
 - the ptsG gene which codes for the glucose-specific IIBC component (Journal of Biological Chemistry 261: 16398-16403 (1986)),
- 25 the 1rp gene which codes for the regulator of the leucine regulon (Journal of Biological Chemistry 266: 10768-10774 (1991)),
- the mopB gene which codes for 10 Kd chaperone (Journal of Biological Chemistry 261: 12414-12419 (1986)) and is also known by the name groES,

25

- the ahpC gene of the ahpCF operon which codes for the small sub-unit of alkyl hydroperoxide reductase (Proceedings of the National Academy of Sciences of the United States of America 92: 7617-7621 (1995)),
- the ahpF gene of the ahpCF operon which codes for the large sub-unit of alkyl hydroperoxide reductase (Proceedings of the National Academy of Sciences of the United States of America 92: 7617-7621 (1995)),
- the cysK gene which codes for cysteine synthase A

 10 (Journal of Bacteriology 170: 3150-3157 (1988)),
 - the cysB gene which codes for the regulator of the cys regulon (Journal of Biological Chemistry 262: 5999-6005 (1987)),
- the cysJ gene of the cysJIH operon which codes for the

 flavoprotein of NADPH sulfite reductase (Journal of
 Biological Chemistry 264: 15796-15808 (1989), Journal of
 Biological Chemistry 264: 15726-15737 (1989)),
- the cysI gene of the cysJIH operon which codes for the haemoprotein of NADPH sulfite reductase (Journal of Biological Chemistry 264: 15796-15808 (1989), Journal of Biological Chemistry 264: 15726-15737 (1989)),
 - the cysH gene of the cysJIH operon which codes for adenylyl sulfate reductase (Journal of Biological Chemistry 264: 15796-15808 (1989), Journal of Biological Chemistry 264: 15726-15737 (1989)),
 - the phoB gene of the phoBR operon which codes for the positive regulator PhoB of the pho regulon (Journal of Molecular Biology 190 (1): 37-44 (1986)),
- the phoR gene of the phoBR operon which codes for the sensor protein of the pho regulon (Journal of Molecular Bisland 190 (1): 518-585 (1906).

3.0

- the phoE gene which codes for protein E of the outer cell membrane (Journal of Molecular Biology 163 (4): 513-532 (1983)),
- the malE gene which codes for the periplasmic binding 5 protein of maltose transport (Journal of Biological Chemistry 259 (16): 10606-10613 (1984)),
 - the pykF gene which codes for fructose-stimulated pyruvate kinase I (Journal of Bacteriology 177 (19): 5719-5722 (1995)),
- the talB gene which codes for transaldolase B (Journal of Bacteriology 177 (20): 5930-5936 (1995)),
 - the rseA gene of the rseABC operon which codes for a membrane protein with anti-sigmaE activity (Molecular Microbiology 24 (2): 355-371 (1997)),
- the rseC gene of the rseABC operon which codes for a global regulator of the sigmaE factor (Molecular Microbiology 24 (2): 355-371 (1997)),
 - the sodA gene which codes for superoxide dismutase (Journal of Bacteriology 155 (3): 1078-1087 (1983)),
- the sucA gene of the sucABCD operon which codes for the decarboxylase sub-unit of 2-ketoglutarate dehydrogenase (European Journal of Biochemistry 141 (2): 351-359 (1984)),
- the sucB gene of the sucABCD operon which codes for the dihydrolipoyltranssuccinase E2 sub-unit of 2-ketoglutarate dehydrogenase (European Journal of Biochemistry 141 (2): 361-374 (1984)),
 - the sucC gene of the sucABCD operon which codes for the β -sub-unit of succinyl-CoA synthetase (Biochemistry 24 (22): 6345-6252 (1985)) and

15

• the sucD gene of the sucABCD operon which codes for the α -sub-unit of succinyl-CoA synthetase (Biochemistry 24 (22): 6245-6252 (1985)),

can be enhanced, in particular over-expressed.

- 5 It may furthermore be advantageous for the production of L-amino acids, in particular L-threonine, in addition to enhancement of the pkfB gene, for one or more of the genes chosen from the group consisting of
- the tdh gene which codes for threonine dehydrogenase 10 (Journal of Bacteriology 169: 4716-4721 (1987)),
 - the mdh gene which codes for malate dehydrogenase (E.C. 1.1.1.37) (Archives in Microbiology 149: 36-42 (1987)),
 - the gene product of the open reading frame (orf) yjfA (Accession Number AAC77180 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
 - the gene product of the open reading frame (orf) ytfp (Accession Number AAC77179 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
- the pckA gene which codes for the enzyme phosphoenol pyruvate carboxykinase (Journal of Bacteriology 172: 7151-7156 (1990)),
 - the poxB gene which codes for pyruvate oxidase (Nucleic Acids Research 14(13): 5449-5460 (1986)),
- the aceA gene which codes for the enzyme isocitrate

 lyase (Journal of Bacteriology 170: 4528-4536 (1988)),
 - the dgsA gene which codes for the DgsA regulator of the phosphotransferase system (Bioscience, Biotechnology and Biochemistry 59: 256-251 (1995)) and is also known under the name of the mlc gene,

- the fruR gene which codes for the fructose repressor (Molecular and General Genetics 226: 332-336 (1991)) and is also known under the name of the cra gene and
- the rpoS gene which codes for the sigma³⁸ factor (WO 01/05939) and is also known under the name of the katF gene,

to be attenuated, in particular eliminated or for the expression thereof to be reduced.

The term "attenuation" in this connection describes the

10 reduction or elimination of the intracellular activity of
one or more enzymes (proteins) in a microorganism which are
coded by the corresponding DNA, for example by using a weak
promoter or a gene or allele which codes for a
corresponding enzyme with a low activity or inactivates the
15 corresponding enzyme (protein) or gene, and optionally
combining these measures.

By attenuation measures, the activity or concentration of the corresponding protein is in general reduced to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the 20 activity or concentration of the wild-type protein or of the activity or concentration of the protein in the starting microorganism.

It may furthermore be advantageous for the production of L-amino acids, in particular L-threonine, in addition to
25 enhancement of the pkfB gene, to eliminate undesirable side reactions (Nakayama: "Breeding of Amino Acid Producing Microorganisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982).

30 The microorganisms produced according to the invention can be cultured in the batch process (batch culture), the fed batch process (feed process) or the repeated fed batch process (repetitive feed process). A summary of known

14

culture methods is described in the textbook by Chmiel (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik [Bioprocess Technology 1. Introduction to Bioprocess Technology (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und

5 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen [Bioreactors and Peripheral Equipment] (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).

The culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington D.C., USA, 1981).

Sugars and carbohydrates, such as e.g. glucose, sucrose,
15 lactose, fructose, maltose, molasses, starch and optionally
cellulose, oils and fats, such as e.g. soya oil, sunflower
oil, groundnut oil and coconut fat, fatty acids, such as
e.g. palmitic acid, stearic acid and linoleic acid,
alcohols, such as e.g. glycerol and ethanol, and organic
20 acids, such as e.g. acetic acid, can be used as the source
of carbon. These substances can be used individually or as
a mixture.

Organic nitrogen-containing compounds, such as peptones, yeast extract, meat extract, malt extract, corn steep

25 liquor, soya bean flour and urea, or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be used as the source of nitrogen. The sources of nitrogen can be used individually or as a mixture.

30 Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as the source of phosphorus. The culture medium must furthermore comprise salts of metals, such as e.g. magnesium sulfate or iron sulfate,

15

which are necessary for growth. Finally, essential growth substances, such as amino acids and vitamins, can be employed in addition to the abovementioned substances. Suitable precursors can moreover be added to the culture medium. The starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.

Basic compounds, such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds, such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH of the culture. Antifoams, such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam. Suitable substances having a selective action, e.g. antibiotics, can be added to the medium to maintain the stability of plasmids. To maintain aerobic conditions, oxygen or oxygen-containing gas mixtures, such as e.g. air, are introduced into the culture. The temperature of the culture is usually 25°C to 45°C, and preferably 30°C to 40°C. Culturing is continued until a maximum of L-amino acids or L-threonine has formed. This target is usually reached within 10 hours to 160 hours.

The analysis of L-amino acids can be carried out by anion exchange chromatography with subsequent ninhydrin
25 derivation, as described by Spackman et al. (Analytical Chemistry 30: 1190-1206 (1958)), or it can take place by reversed phase HPLC as described by Lindroth et al. (Analytical Chemistry 51: 1167-1174 (1979)).

The process according to the invention is used for the

30 fermentative preparation of L-amino acids, such as, for
example, L-threonine, L-isoleucine, L-valine, L-methionine,
L-homoserine and L-lysine, in particular L-threonine.

The present invention is explained in more detail in the following with the aid of embodiment examples.

The minimal (M9) and complete media (LB) for Escherichia coli used are described by J.H. Miller (A Short Course in Bacterial Genetics (1992), Cold Spring Harbor Laboratory Press). The isolation of plasmid DNA from Escherichia coli and all techniques of restriction, ligation, Klenow and alkaline phosphatase treatment are carried out by the method of Sambrook et al. (Molecular Cloning - A Laboratory Manual (1989) Cold Spring Harbor Laboratory Press). Unless described otherwise, the transformation of Escherichia coli is carried out by the method of Chung et al. (Proceedings of the National Academy of Sciences of the United States of America 86: 2172-2175 (1989)).

The incubation temperature for the preparation of strains and transformants is 37°C.

15 Example 1

Construction of the expression plasmid pTrc99ApfkB

The pfkB gene from E. coli K12 is amplified using the polymerase chain reaction (PCR) and synthetic oligonucleotides. Starting from the nucleotide sequence of the pfkB gene in E. coli K12 MG1655 (Accession Number AE000276, Blattner et al. (Science 277: 1453-1462 (1997)), PCR primers are synthesized (MWG Biotech, Ebersberg, Germany). The sequences of the primers are modified such that recognition sites for restriction enzymes are formed.

25 The recognition sequence for XbaI is chosen for the pfkB1 primer and the recognition sequence for HindIII for the pfkB2 primer, which are marked by underlining in the nucleotide sequence shown below:

- pfkB1: 5' GGTGCCAGTCTAGAATCTGACTATAG 3' (SEQ ID No. 1)
- 30 pfkB2: 5' GTTGCCGAAAGCTTGGTGATGATTC 3' (SEQ ID No. 2)

 The chromosomal E. coli K12 MG1655 DNA employed for the PCR
 LS LSULATED MCCGALING to this manufactument's innutritations

with "Qiagen Genomic-tips 100/G" (QIAGEN, Hilden, Germany).

A DNA fragment approx. 1000 bp in size can be amplified with the specific primers under standard PCR conditions (Innis et al. (1990) PCR Protocols. A guide to methods and applications, Academic Press) with Pfu-DNA polymerase (Promega Corporation, Madison, USA).

The PCR product is ligated according to the manufacturer's instructions with the vector pCR-Blunt II-TOPO (Zero Blunt TOPO PCR Cloning Kit, Invitrogen, Groningen, The

- 10 Netherlands) and transformed into the E. coli strain TOP10. Selection of plasmid-carrying cells takes place on LB agar, to which 50 μg/ml kanamycin are added. After isolation of the plasmid-DNA, the vector pCR-Blunt II-TOPO-pfkB is cleaved with the restriction enzymes HindIII and XbaI and,
- 15 after separation in 0.8% agarose gel, the pfkB fragment is isolated with the aid of the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany). The vector pTrc99A (Pharmacia Biotech, Uppsala, Sweden) is cleaved with the enzymes HindIII and XbaI and ligation is carried out with the pfkB 20 fragment isolated.

The E. coli strain XL1-Blue MRF' (Stratagene, La Jolla, USA) is transformed with the ligation batch and plasmid-carrying cells are selected on LB agar, to which 50 μ g/ml ampicillin are added. Successful cloning can be

25 demonstrated after plasmid DNA isolation by control cleavage with the enzymes AccI, BamHI and Tth111I. The plasmid is called pTrc99ApfkB (Figure 1).

Example 2

Preparation of L-threonine with the strain 30 MG442/pTrc99ApfkB

The L-threonine-producing E. coli strain MG442 is described in the patent specification US-A- 4,278,765 and deposited

as CMIM B-1628 at the Russian National Collection for Industrial Microorganisms (VKPM, Moscow, Russia).

The strain MG442 is transformed with the expression plasmid pTrc99ApfkB described in example 1 and with the vector

- 5 pTrc99A and plasmid-carrying cells are selected on LB agar with 50 µg/ml ampicillin. The strains MG442/pTrc99ApfkB and MG442/pTrc99A are formed in this manner. Selected individual colonies are then multiplied further on minimal medium with the following composition: 3.5 g/l Na₂HPO₄*2H₂O,
- 10 1.5 g/l KH₂PO₄, 1 g/l NH₄Cl, 0.1 g/l MgSO₄*7H₂O, 2 g/l glucose, 20 g/l agar, 50 mg/l ampicillin. The formation of L-threonine is checked in batch cultures of 10 ml contained in 100 ml cónical flasks. For this, 10 ml of preculture medium of the following composition: 2 g/l yeast extract,
- 15 10 g/l $(NH_4)_2SO_4$, 1 g/l KH_2PO_4 , 0.5 g/l $MgSO_4*7H_2O$, 15 g/l CaCO₃, 20 g/l glucose, 50 mg/l ampicillin are inoculated and the batch is incubated for 16 hours at 37°C and 180 rpm on an ESR incubator from Kühner AG (Birsfelden, Switzerland).
- 20 250 µl portions of this preculture are transinoculated into 10 ml of production medium (25 g/l (NH₄)₂SO₄, 2 g/l KH₂PO₄, $1 \text{ g/1 MgSO}_4*7H_2O$, $0.03 \text{ g/1 FeSO}_4*7H_2O$, $0.018 \text{ g/1 MnSO}_4*1H_2O$, 30 g/l $CaCO_3$, 20 g/l glucose, 50 mg/l ampicillin) and the batch is incubated for 48 hours at 37°C. The formation of
- 25 L-threonine by the starting strain MG442 is investigated in the same manner, but no addition of ampicillin to the medium takes place. After the incubation the optical density (OD) of the culture suspension is determined with an LP2W photometer from Dr. Lange (Düsseldorf, Germany) at 30 a measurement wavelength of 660 nm.
- The concentration of L-threonine formed is then determined in the sterile-filtered culture supernatant with an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column reaction 35 with ninhydrin detection.

The result of the experiment is shown in Table 1.

Table 1

Strain	OD (660 nm)	L-Threonine g/l
MG442	5.6	1.4
MG442/pTrc99A	3.8	1.3
MG442/pTrc99ApfkB	5.6	2.1

Brief Description of the Figure:

5 Figure 1: Map of the plasmid pTrc99ApfkB containing the pfkB gene.

The length data are to be understood as approx. data. The abbreviations and designations used have the following meaning:

10 • Amp: Ampicillin resistance gene

• lacI: Gene for the repressor protein of the tro

• Ptrc: trc promoter region, IPTG-inducible

pfkB: Coding region of the pfkB gene

15 • 5S: 5S rRNA region

• rrnBT: rRNA terminator region

The abbreviations for the restriction enzymes have the following meaning

• AccI: Restriction endonuclease from Acinetobacter calcoaceticus

- BamHI: Restriction endonuclease from Bacillus amyloliquefaciens H
- HindIII: Restriction endonuclease from Haemophilus influenzae
- 5 Tth111I: Restriction endonuclease from Thermus thermophilus 111
 - XbaI: Restriction endonuclease from Xanthomonas campestris

What is claimed is:

15

30

- 1. A process for the preparation of L-amino acids, in particular L-threonine, which comprises carrying out the following steps:
- 5 a) fermentation of microorganisms of the
 Enterobacteriaceae family which produce the desired
 L-amino acid and in which at least the pfkB gene,
 or the nucleotide sequence which codes for this, is
 enhanced, in particular over-expressed,
- 10 b) concentration of the desired L-amino acid in the medium or in the cells of the microorganisms, and
 - c) isolation of the desired L-amino acid, constituents of the fermentation broth and/or the biomass in its entirety or portions (> 0 to 100%) thereof optionally remaining in the product.
 - A process as claimed in claim 1, wherein microorganisms in which further genes of the biosynthesis pathway of the desired L-amino acid are additionally enhanced are employed.
- 20 3. A process as claimed in claim 1, wherein microorganisms in which the metabolic pathways which reduce the formation of the desired L-amino acid are at least partly eliminated are employed.
- 4. A process as claimed in claim 1, wherein the expression of the polynucleotide which codes for the pfkB gene is increased.
 - 5. A process as claimed in claim 1, wherein the regulatory and/or catalytic properties of the polypeptide (protein) for which the polynucleotide pfkB codes are improved or increased.

5

- 6. A process as claimed in claim 1, wherein, for the preparation of L-amino acids, microorganisms of the Enterobacteriaceae family in which in addition at the same time one or more of the genes chosen from the group consisting of: the thrABC operon which codes for aspartate 6.1
 - kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase,
- the pyc gene which codes for pyruvate 6.2 carboxylase, 10
 - the pps gene which codes for phosphoenol 6.3 pyruvate synthase,
 - the ppc gene which codes for phosphoenol 6.4 pyruvate carboxylase,
- the pntA and pntB genes which code for 15 6.5 transhydrogenase,
 - the rhtB gene which imparts homoserine 6.6 resistance,
- the mgo gene which codes for malate:quinone 6.7 oxidoreductase, 20
 - the rhtC gene which imparts threonine 6.8 resistance,
 - the thrE gene which codes for the threonine 6.9 export protein,
- the gdhA gene which codes for glutamate 6.10 25 dehydrogenase,
 - the hns gene which codes for the DNA-binding 6.11 protein HLP-II,

	6.12	the pgm gene which codes for phosphoglucomutase,
	6.13	the fba gene which codes for fructose biphosphate aldolase,
5	6.14	the ptsH gene which codes for the phosphohistidine protein hexose phosphotransferase,
	6.15	the ptsI gene which codes for enzyme I of the phosphotransferase system,
.0	6.16	the crr gene which codes for the glucose- specific IIA component,
	6.17	the ptsG gene which codes for the glucose- specific IIBC component,
15	6.18	the lrp gene which codes for the regulator of the leucine regulon,
	6.19	the mopB gene which codes for 10 Kd chaperone,
	6.20	the ahpC gene which codes for the small sub- unit of alkyl hydroperoxide reductase,
20	6.21	the ahpF gene which codes for the large sub- unit of alkyl hydroperoxide reductase,
	6.22	the cysK gene which codes for cysteine synthas A,
	6.23	the cysB gene which codes for the regulator of the cys regulon,
25	6.24	the cysJ gene which codes for the flavoprotein of NADPH sulfite reductase,
	6.25	the cysI gene which codes for the haemoprotein of NADPH sulfite reductase,

	6.26	reductase,
	6.27	the phoB gene which codes for the positive regulator PhoB of the pho regulon,
5	6.28	the phoR gene which codes for the sensor protein of the pho regulon,
	6.29	the phoE gene which codes for protein E of outer cell membrane,
10	6.30	the malE gene which codes for the periplasmic binding protein of maltose transport
	6.31	the pykF gene which codes for fructose- stimulated pyruvate kinase I,
	6.32	the talB gene which codes for transaldolase B,
15	6.33	the rseA gene which codes for a membrane protein which acts as a negative regulator on sigmaE activity,
	6.34	the rseC gene which codes for a global regulator of the sigmaE factor,
20	6.35	the sodA gene which codes for superoxide dismutase,
	6.36	the sucA gene which codes for the decarboxylase sub-unit of 2-ketoglutarate dehydrogenase,
25	6.37	the sucB gene which codes for the dihydrolipoyltranssuccinase E2 sub-unit of 2-ketoglutarate dehydrogenase,
	6.38.	the sucC gene which codes for the β -sub-unit of succinyl-CoA synthetase,

6.39 the sucD gene which codes for the α-sub-unit of succinyl-CoA synthetase,

is or are enhanced, in particular over-expressed, are fermented.


- 5 7. A process as claimed in claim 1, wherein, for the preparation of L-amino acids, microorganisms of the Enterobacteriaceae family in which in addition at the same time one or more of the genes chosen from the group consisting of:
- 10 7.1 the tdh gene which codes for threonine dehydrogenase,
 - 7.2 the mdh gene which codes for malate dehydrogenase,
- 7.3 the gene product of the open reading frame (orf) yjfA,
 - 7.4 the gene product of the open reading frame (orf) ytfP,
 - 7.5 the pckA gene which codes for phosphoenol pyruvate carboxykinase,
- 20 7.6 the poxB gene which codes for pyruvate oxidase,
 - 7.7 the aceA gene which codes for isocitrate lyase,
 - 7.8 the dgsA gene which codes for the DgsA regulator of the phosphotransferase system,
- 7.9 the fruR gene which codes for the fructose repressor,
 - 7.10 the rpoS gene which codes for the sigma³⁸ factor

is or are attenuated, in particular eliminated or reduced in expression, are fermented.

WO 03/008610 PCT/EP02/07368

Figure 1:

1/1



SEQUENCE PROTOCOL

5	<110>	Degussa AG	
J	<120>	Process for the preparation of L-amino acids using strains of the Enterobacteriaceae family which contain an enhanced pfkB gene	
10	<130>	020283BT	
•	<160>	2	
15	<170>	PatentIn version 3.1	•
	<210> <211> <212>	26	
20	<213> <220>	artificial sequence	
25		Primer (1)(26) pfkB1	
23	<400> ggtgcc	1 agtc tagaatctga ctatag	26
30	<210> <211> <212> <213>	25	
35	<222>	Primer (1)(25) pfkB2	
40		2 gaaa gcttggtgat [.] gattc	25

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 30 January 2003 (30.01.2003)

PCT

(10) International Publication Number WO 2003/008610 A3

(51) International Patent Classification7: C12N 15/54. 9/12, C12P 13/08 // (C12P 13/08, C12R 1:19)

(21) International Application Number:

PCT/EP2002/007368

(22) International Filing Date:

3 July 2002 (03.07.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

101 35 053.8 60/306,869

18 July 2001 (18.07.2001) DE 23 July 2001 (23.07.2001)

(71) Applicant (for all designated States except US): DE-GUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düsseldorf (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): RIEPING, Mechthild [DE/DE]; Mönkebergstrasse 1, 33619 Bielefeld (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Deciaration under Rule 4.17:

of inventorship (Rule 4.17(iv)) for US only


Published:

with international search report

(88) Date of publication of the international search report: 8 January 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE ENTEROBACTERIACEAE FAMILY WHICH CONTAIN AN ENHANCED PFKB GENE



(57) Abstract: The invention relates to a process for the preparation of L-amino acids, in particular L-threonine, in which the following steps are carried out: a) fermentation of microorganisms of the Enteropacteriaceae family which produce the desired L-amino acid and in which at least the pfkB gene, or the nucleotide sequence which codes for this, is enhanced, in particular over-expressed. b) concentration of the desired L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the desired L-amino

Interna Application No PCT/EP 02/07368

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/54 C12N C12N9/12 C12P13/08 //(C12P13/08,C12R1:19) According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C12P Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Category Citation of document, with indication, where appropriate, of the relevant passages Y EP 0 994 190 A (AJINOMOTO KK) 1-7 19 April 2000 (2000-04-19) the whole document example 4 claims 6,7,10,11 P,A EP 1 195 431 A (AJINOMOTO KK) 1-7 10 April 2002 (2002-04-10) the whole document example 1 claim 4 -& WO OO 77172 A (SUGIMOTO MASAKAZU :ITO 1-7 HISAO (JP); AJINOMOTO KK (JP); IZUI HIROSHI) 21 December 2000 (2000-12-21) the whole document Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the A document defining the general state of the art which is not considered to be of particular relevance invention 'E' earlier document but published on or after the international *X* document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled *P* document published prior to the international filing date but later than the priority date claimed in the art. '&' document member of the same patent family Date of the actual completion of the International search Date of mailing of the international search report 11 June 2003 30/06/2003 Name and mailing address of the iSA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 van de Kamp, M

Intel Application No PCI/EF 02/07368

	tion) DOCUMENTS CONSIDERED TO BE RELEVANT	0.51
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 1 103 613 A (DEGUSSA) 30 May 2001 (2001-05-30) the whole document	1-7
A	EMMERLING M ET AL.: "Altered regulation of pyruvate kinase or co-overexpression of phosphofructokinase increases glycolytic fluxes in resting Escherichia coli." BIOTECHNOLOGY AND BIOENGINEERING, vol. 67, no. 5, 5 March 2000 (2000-03-05), pages 623-627, XP002243936 ISSN: 0006-3592 abstract	1-7
A	EMMERLING M ET AL.: "Glucose catabolism of Escherichia coli strains with increased activity and altered regulation of key glycolytic enzymes." METABOLIC ENGINEERING, vol. 1, no. 2, April 1999 (1999-04), pages 117-127, XP002243937 ISSN: 1096-7176 abstract	1-7
А	DALDAL F: "Nucleotide sequence of gene pfkB encoding the minor phosphofructokinase of Escherichia coli K-12" GENE, vol. 28, 1984, pages 337-342, XP002927750 ISSN: 0378-1119 cited in the application abstract	1-7
A	WO 99 53035 A (ALTMAN ELLIOT ; GOKARN RAVI R (US); EITEMAN MARK A (US); UNIV GEORG) 21 October 1999 (1999-10-21) page 5, line 20-24 examples 4,7,9,10 claims 31,38,41,49 figures 1,4	1-7
A	MICHAL G: "Biochemical pathways: an atlas of biochemistry and molecular biology" 1999 , JOHN WILEY & SONS INC. AND SPEKTRUM AKADEMISCHER VERLAG , NEW YORK — HEIDELBERG XP002242199 ISBN: 0-471-33130-9 figure 3.8-2 figures 4.2-1, 4.5-1 and 4.5-2	1-7

Inte upplication No PCI/EP 02/07368

Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	1
Category •	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KRAEMER R: "Genetic and physiological approaches for the production of amino acids" JOURNAL OF BIOTECHNOLOGY, vol. 45, no. 1, 1996, pages 1-21, XP002178648 ISSN: 0168-1656 the whole document	1-7
A	JETTEN M S M ET AL.: "Recent advances in the physiology and genetics of amino acid-producing bacteria." CRC CRITICAL REVIEWS IN BIOTECHNOLOGY, vol. 15, no. 1, 1995, pages 73-103, XP000613291 ISSN: 0738-8551 figure 1 page 90, left-hand column, line 1 -page 92, left-hand column, line 17	1-7
A	US 4 278 765 A-(DEBABOV VLADIMIR G ET AL) 14 July 1981 (1981-07-14) cited in the application the whole document	1-7
Α.	EP 0 643 135 A (AJINOMOTO KK) 15 March 1995 (1995-03-15) the whole document	1-7
A	EP 0 237 819 A (KYOWA HAKKO KOGYO KK) 23 September 1987 (1987-09-23) the whole document	1-7
A	DATABASE WPI Section Ch, Week 199148 Derwent Publications Ltd., London, GB; Class B05, AN 1991-351136 XP002241222 & JP 03 236786 A (KYOWA HAKKO-KOGYO KK), 22 October 1991 (1991-10-22) abstract	1-7
E	WO 03 008605 A (RIEPING MECHTHILD ; DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
E	WO 03 008606 A (RIEPING MECHTHILD ; DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
·		

Inter d Application No PCI/EP 02/07368

C/Continu	etion) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *		Relevant to claim No.
Odlegory	onation of document, with management, made appropriate, of the relevant passages	Resvalt to Claim No.
E	WO 03 008607 A (RIEPING MECHTHILD ;DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
E	WO 03 008608 A (RIEPING MECHTHILD ;DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
E	WO 03 008609 A (RIEPING MECHTHILD ;DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
E	WO 03 008611 A (RIEPING MECHTHILD ;DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
E	WO 03 008612 A (RIEPING MECHTHILD ;DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
E	WO 03 008613 A (RIEPING MECHTHILD ;DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
E	WO 03 008614 A (RIEPING MECHTHILD ;DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
E	WO 03 008615 A (RIEPING MECHTHILD ;DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1–7
T	WO 03 008600 A (DEGUSSA ;HERMANN THOMAS (DE)) 30 January 2003 (2003-01-30) the whole document claim 1	1–7
	·	

Inte Pl Application No PCI/EP 02/07368

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
EP 0994190	Α	19-04-2000	RU	2144564		20-01-2000
			AU	4755099		20-04-2000
			BR	9904955		12-12-2000
			CN	1254014	Α	24-05-2000
			EP	0994190		19-04-2000
			JP	2000116390		25-04-2000
			KR	2000029006		25-05-2000
			SK	140899		16-05-2000
			ÜŜ	6303348		16-10-2001
			US	2002102670		01-08-2002
			US	2002058314		16-05-2002
			ZA	9906042		04-04-2000
EP 1195431	Α	10-04-2002	AU BR	5106800 0011672		02-01-2001
						19-03-2002
			EP	1195431		10-04-2002
			CN	1370228		18-09-2002
			WO	0077172	A1 -	21-12-2000
EP 1103613	Α	30-05-2001	DE	19956131		31-05-2001
			AU	7166500		24-05-2001
	-		BR	0005543	Α	07-08-2001
			CA	2323750	A 1	23-05-2001
		•	CN	1297055		30-05-2001
			EP	1103613		30-05-2001
			ΗÜ	0004676		28-10-2002
			JP	2001186895		10-07-2001
			PL	344076		04-06-2001
			SK	17362000		08-10-2001
WO 9953035	Α	21-10-1999	AU	760575	 R2	15-05-2003
			AU	3555999		01-11-1999
			BR	9909615		12-12-2000
			CA	2325598		21-10-1999
			EP	1073722		07-02-2001
			JP		A I	16-04-2002
			WO		-	21-10-1999
			US	9953035		
			US	2003087381		08-05-2003
				6455284		24-09-2002
US 4278765	Α	14-07-1981	SU	875663		15-09-1982
			HU	190999	 R	28-12-1986
EP 0643135	Α	15-03-1995	AT	203769		15-08-2001
		•	CZ	9401658		15-12-1994
			DE	69330518		06-09-2001
			DE	69330518	T2	08-05-2002
			DK	643135	Т3	15-10-2001
	6	•	EP	0643135		15-03-1995
			JP	3331472		07-10-2002
			SK	81994		10-05-1995
			US	5661012		26-08-1997
			EP	1020526		19-07-2000
			ES	2158867		16-09-2001
			WO	9411517		26-05-1994
			RU	2113484	C1	20-06-1998
EP 0237819		23-09-1987	RU DE	2113484 (3788583 I	~	20-06-1998 10-02-1994

Inter Application No PCI/EF 02/07368

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
EP 0237819 A	· · · · · · · · · · · · · · · · · · ·	DE EP JP JP KR US	3788583 T2 0237819 A2 2574786 B2 63273487 A 9108634 B1 5017483 A	19-05-1994 23-09-1987 22-01-1997 10-11-1988 19-10-1991 21-05-1991
JP 3236786 A	22-10-1991	JP	2877414 B2	31-03-1999
WO 03008605 A	30-01-2003	DE WO WO WO WO WO WO WO	10135053 A1 03008605 A2 03008606 A2 03008607 A2 03008608 A2 03008609 A2 03008610 A2 03008611 A2 03008612 A2 03008613 A2 03008614 A2 03008615 A2	06-02-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003
WO 03008606 A	30-01-2003	DE WO WO WO WO WO WO WO	10135053 A1 03008605 A2 03008606 A2 03008607 A2 03008608 A2 03008609 A2 03008610 A2 03008611 A2 03008612 A2 03008613 A2 03008614 A2 03008615 A2	06-02-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003
WO 03008607 A	30-01-2003	DE WO WO WO WO WO WO WO	10135053 A1 03008605 A2 03008606 A2 03008607 A2 03008608 A2 03008609 A2 03008610 A2 03008611 A2 03008612 A2 03008613 A2 03008614 A2 03008615 A2	06-02-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003
WO 03008608 A	30-01-2003	DE WO WO WO WO WO	10135053 A1 03008605 A2 03008606 A2 03008607 A2 03008608 A2 03008609 A2 03008610 A2 03008611 A2 03008612 A2 03008613 A2	06-02-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003

PCI/Er 02/07368

					1
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 03008608	Α		WO	03008614 A2	30-01-2003
	•••		MO	03008615 A2	30-01-2003
WO 03008609	Α	30-01-2003	DE	10135053 A1	06-02-2003
			WO	03008605 A2	30-01-2003
			WO WO	03008606 A2 03008607 A2	30-01-2003
			WO	03008607 AZ	30-01-2003 30-01-2003
			WO	03008609 A2	30-01-2003
			WO	03008610 A2	30-01-2003
			WO	03008611 A2	30-01-2003
			WO	03008612 A2	30-01-2003
			MO	03008613 A2	30-01-2003
			WO	03008614 A2	30-01-2003
			WO	03008615 A2	30-01-2003
WO 03008611	Α	30-01-2003	DE	10135053 A1	06-02-2003
	. •		WO	03008605 A2	30-01-2003
•			WO	03008606 A2	30-01-2003
			MO	03008607 A2	30-01-2003
			MO	03008608 A2	30-01-2003
	•		WO	03008609 A2	30-01-2003
•			WO	03008610 A2	30-01-2003
			WO WO	03008611 A2 03008612 A2	30-01-2003 30-01-2003
	•		WO	03008612 A2	30-01-2003
		•	WO .	03008614 A2	30-01-2003
		•	WO	03008615 A2	30-01-2003
WO 03008612	Α	30-01-2003	DE	10135053 A1	06-02-2003
WO 03008012	^	30-01-2003	WO	03008605 A2	30-01-2003
			WO	03008606 A2	30-01-2003
,		•	WO	03008607 A2	30-01-2003
			WO	03008608 A2	30-01-2003
			WO	03008609 A2	30-01-2003
			MO	03008610 A2	30-01-2003
			MO	03008611 A2	30-01-2003
			WO	03008612 A2	30-01-2003
			WO WO	03008613 A2 03008614 A2	30-01-2003 30-01-2003
			WO	03008615 A2	30-01-2003
		20 07 2005			
WO 03008613	Α	30-01-2003	DE	10135053 A1	06-02-2003
			MO	03008605 A2 03008606 A2	30-01-2003 30-01-2003
			WO WO	03008606 A2 03008607 A2	30-01-2003
			WO	03008607 A2	30-01-2003
			WO	03008609 A2	30-01-2003
		•	WO	03008610 A2	30-01-2003
			WO	03008611 A2	30-01-2003
		-	WO	03008612 A2	30-01-2003
			WO	03008613 A2	30-01-2003
		•	WO	03008614 A2	30-01-2003
			WO	03008615 A2	30-01-2003
	Α	30-01-2003	DE	10135053 A1	06-02-2003
WO 03008614	T.	00 01 2000			
WO 03008614	Λ.	00 01 2000	WO	03008605 A2	30-01-2003

PCI/EP 02/07368

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 03008614			WO	03008607 A2	20 01 2002
NO 0000014	^		WO		30-01-2003
			WO	03008608 A2	30-01-2003
			WO	03008609 A2	30-01-2003
			WO	03008610 A2	30-01-2003
			WO	03008611 A2 03008612 A2	30-01-2003
			WO	03008612 AZ 03008613 A2	30-01-2003
			MO .		30-01-2003
			WO	03008614 A2	30-01-2003
			WU	03008615 A2	30-01-2003
WO 03008615	Α	30-01-2003	DE	10135053 A1	06-02-2003
			WO	03008605 A2	30-01-2003
		•	WO	03008606 A2	30-01-2003
			WO	03008607 A2	30-01-2003
			MO	03008608 A2	30-01-2003
			WO	03008609 A2	30-01-2003
			WO	03008610 A2	30-01-2003
			WO	03008611 A2	30-01-2003
			WO	03008612 A2	30-01-2003
			WO	03008613 A2	30-01-2003
			WO	03008614 A2	30-01-2003
	•		WO	03008615 A2	30-01-2003
WO 03008600	A	30-01-2003	DE	10135051 A1	06-02-2003
		11 11 1000	WO	03008600 A2	30-01-2003
			WO	03008602 A2	30-01-2003
			WO	03008603 A2	30-01-2003
•			WO	03008604 A2	30-01-2003
			MO	03008616 A2	30-01-2003